BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saniabadi AR, Tanaka T, Yamamoto T, Kruis W, Sacco R. Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: Concepts and clinical features for better therapeutic outcomes. J Clin Apher. 2019;34:51-60. [PMID: 30407662 DOI: 10.1002/jca.21670] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Lezzar DL, Lam FW, Huerta R, Mukhamedshin A, Lu M, Shevkoplyas SS. A high-throughput microfluidic device based on controlled incremental filtration to enable centrifugation-free, low extracorporeal volume leukapheresis. Sci Rep 2022;12:13798. [PMID: 35963876 DOI: 10.1038/s41598-022-16748-5] [Reference Citation Analysis]
2 Bamias G, Zampeli E, Domènech E. Targeting neutrophils in inflammatory bowel disease: revisiting the role of adsorptive granulocyte and monocyte apheresis. Expert Rev Gastroenterol Hepatol 2022. [PMID: 35833363 DOI: 10.1080/17474124.2022.2100759] [Reference Citation Analysis]
3 Horton RK, Summerfield DD, Winters JL. The use of therapeutic apheresis in allergic and immunological diseases. Allergic and Immunologic Diseases 2022. [DOI: 10.1016/b978-0-323-95061-9.00054-0] [Reference Citation Analysis]
4 Ueno N, Sugiyama Y, Kobayashi Y, Murakami Y, Iwama T, Sasaki T, Kunogi T, Takahashi K, Tanaka K, Ando K, Kashima S, Inaba Y, Moriichi K, Tanabe H, Taruishi M, Saitoh Y, Okumura T, Fujiya M. Fecal calprotectin is a useful biomarker for predicting the clinical outcome of granulocyte and monocyte adsorptive apheresis in ulcerative colitis patients: a prospective observation study. BMC Gastroenterol 2021;21:316. [PMID: 34362299 DOI: 10.1186/s12876-021-01889-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Woźniak M, Kurnatowska I, Małecka-Panas E, Talar-Wojnarowska R. Leukocytapheresis in patients with inflammatory bowel diseases. Prz Gastroenterol 2021;6:99-105. [PMID: 34276835 DOI: 10.5114/pg.2021.106658] [Reference Citation Analysis]
6 Domènech E, Grífols JR, Akbar A, Dignass AU. Use of granulocyte/monocytapheresis in ulcerative colitis: A practical review from a European perspective. World J Gastroenterol 2021; 27(10): 908-918 [PMID: 33776362 DOI: 10.3748/wjg.v27.i10.908] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
7 Kashiwagi N, Saito F, Maegawa H, Kaneda K. Granulocyte and monocyte adsorptive apheresis induces apoptosis of neutrophils and release of a novel chemoattractant for desensitization of interleukin-8 response - In vitro and in vivo results. Cytokine 2021;139:155410. [PMID: 33395614 DOI: 10.1016/j.cyto.2020.155410] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Ishiguro Y, Ohmori T, Umemura K, Iizuka M. Factors associated with the outcomes in ulcerative colitis patients undergoing granulocyte and monocyte adsorptive apheresis as remission induction therapy: A multicenter cohort study. Ther Apher Dial 2021;25:502-12. [PMID: 33029920 DOI: 10.1111/1744-9987.13594] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Chen XL, Mao JW, Wang YD. Selective granulocyte and monocyte apheresis in inflammatory bowel disease: Its past, present and future. World J Gastrointest Pathophysiol 2020; 11(3): 43-56 [PMID: 32435521 DOI: 10.4291/wjgp.v11.i3.43] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Li N, Mao J, Tang H, Zhu L, Tan X, Bi J, Wu H, Chen X, Wang Y. Efficacy and safety of adsorptive granulomonocytapheresis in Chinese patients with ulcerative colitis: A retrospective analysis of 50 cases with focus on factors impacting clinical efficacy. J Clin Apher 2020;35:271-80. [PMID: 32378240 DOI: 10.1002/jca.21787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Rodríguez-Lago I, Benítez JM, Sempere L, Sáez-González E, Barreiro-de Acosta M, de Zárate JO, Cabriada JL. The combination of granulocyte-monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis? J Clin Apher 2019;34:680-5. [PMID: 31518013 DOI: 10.1002/jca.21746] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
12 Yanagisawa K, Murakami M, Kondo Y, Oguma S, Kobayashi S, Miyasaka H, Shinohara T, Tomori A, Nakano Y, Furuhata S, Ikezoe M. Efficacy and Safety of Adsorptive Granulocyte and Monocyte Apheresis in Elderly and Pregnant Patients With Ulcerative Colitis. Ther Apher Dial 2019;23:217-23. [PMID: 31025815 DOI: 10.1111/1744-9987.12818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Schoultz I, Keita ÅV. Cellular and Molecular Therapeutic Targets in Inflammatory Bowel Disease-Focusing on Intestinal Barrier Function. Cells 2019;8:E193. [PMID: 30813280 DOI: 10.3390/cells8020193] [Cited by in Crossref: 85] [Cited by in F6Publishing: 89] [Article Influence: 28.3] [Reference Citation Analysis]